Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents
Research article
[키워드] antibody
antiviral agent
Antiviral agents
blocking
Blood
Cancer
cancers
CD8
CD8+
CD8+ cell
Cell
Chloroquine
clinical trials
COVID-19
COVID-19 infected patient
COVID-19 patient
CTLs
cytokine secretion
cytotoxic
cytotoxicity
disease
Disease progression
effective
functional
generate
healthy controls
healthy individuals
Host
immune response
Immunity
individual
inhibiting
inhibitory
Innate
innate immune response
Innate immunity
interferon
lymphocyte
mechanism
mild infection
modulated
Monalizumab
natural
neutrophil
NK cell
NK cell function
NK cells
NKG2A
Novel coronavirus
outbreak
over-expressing
overexpression
Patient
Phase 2
Potential treatment
receptor
receptors
reduced
required
resulting
SARS
SARS-CoV-2
severe COVID-19
Severe infection
Side effect
significantly
significantly lower
T-cell
treated
tumor growth
tumor progression
viral pathogen
viruses
weakened immune system
[DOI] 10.1016/j.mehy.2020.109777 [Article Type] Research article
[DOI] 10.1016/j.mehy.2020.109777 [Article Type] Research article